Comparing the current results to its competitors, Vera Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.59 %, recorded in the same quarter.
Vera Therapeutics Inc , slower than the average decrease reported by the company's competitors of -50.65 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -50.65 %
Vera Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape encompasses the success of existing and potential competing therapies, as well as developments related to competitors and the industry, including competing product candidates and therapies.
November 11, 2024
Vera Therapeutics Partners with University of Michigan Amid Revenue Challenges BRISBANE, Calif. Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology firm focused on development and commercialization of treatments for serious immunological diseases, has announced a partnership with the University of Michigan. This collaboration is aimed at advancing the Nephrotic Syndrome Study Network (NEPTUNE), specifically through the NEPTUNE Match project and the PIONEER Study. This strategic alliance is anticipated to enhance the understanding of nephrotic syndrome, a serious kidney disorder, and possibly lead to new treatment avenues for patients suffering from this condition.Despite this promis...
October 2, 2024
Navigating Clinical Progress and Market Challenges: Vera Therapeutics’ ORIGIN Phase 2b Trial Results at ASN Kidney Week 2024 Vera Therapeutics recently announced a late-breaking oral presentation of the long-term results from their ORIGIN Phase 2b clinical trial at the prestigious American Society of Nephrology (ASN) Kidney Week 2024. This development marks a significant milestone in the biosciences firm’s ongoing research efforts, set against a backdrop of recent stock market underperformance. Clinical Breakthroughs in Nephrology The ORIGIN Phase 2b trial is a testament to Vera Therapeutics’ dedication to developing innovative treatments for kidney-related diseases. Through its presentation at ASN Kid...
January 25, 2024
IgA nephropathy is a chronic kidney disease characterized by the deposition of IgA immunoglobulins in the glomeruli. It is the most common primary glomerulonephritis worldwide, often resulting in progressive decline in renal function and necessitating renal replacement therapy. The development of effective treatment strategies that can halt or slow the progression of IgA nephropathy is crucial. In this article, we present the findings from the Phase 2b Open-Label Extension (OLE) of the ORIGIN Clinical Trial, highlighting the therapeutic potential of atacicept in stabilizing renal function over a 72-week treatment period.Methods:The ORIGIN Clinical Trial OLE included participants with IgA nephropathy who had ...
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Sources:
Vera Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vera Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
